Regeneron earnings beat forecasts as stronger Sanofi profits lift revenue
Earnings results
- EPS beat +22.2%
Actual: $20.07 · Cons.: $16.42 (non-GAAP diluted EPS)
- Revenue beat +12.2%
Actual: $5.1158B · Cons.: $4.56B (reported total revenue)
- Guidance
2026 adjusted product gross margin raised to about 86% from 84%–85%; adjusted R&D spending raised to $6.05–$6.15B
Earnings and the stock move
The newly released earnings show improving partnership economics alongside commercial growth. Investors should separate durable medicine demand and a larger profit share from the upcoming upfront payment, which belongs to a later quarter.
Q3 2026 ended September 30 earnings recap
Regeneron rose 7.1% pre-market on October 30, 2026 after earnings beat forecasts. Stronger Sanofi collaboration profits helped lift revenue.
- Adjusted EPS, or profit per share excluding specified accounting items, reached $20.07 versus the $16.42 forecast. GAAP profit per share was $18.45.
- Revenue reached $5.12 billion versus the $4.56 billion forecast, a 12.2% beat. The company earns both medicine sales and income from development partnerships.
- Sanofi collaboration income benefited from stronger Dupixent demand and the end of repayments for earlier development costs. That improves Regeneron’s share of partnership economics.
- Eylea HD sales in the U.S. rose 62% to $699 million, but combined sales with the older Eylea declined 1%. Competition remains a risk despite the newer treatment’s growth.
- The expanded Sanofi agreement brings $1 billion upfront, to be recognized in the fourth quarter. Up to $7 billion of further payments depends on milestones; it is not guaranteed revenue.
- The annual adjusted product gross-margin outlook rose to about 86% from 84%–85%. Higher research spending means part of the commercial improvement will fund future medicines.
Watch the next regular session for follow-through and whether product demand sustains the profit improvement. The charts end at the October 29 close, before these results; drug-development and pricing risks remain.
Financials and technicals
Charts through Oct 29, 2026. The session move above may reflect later news.
Technical setup and risks
The October 29 completed charts precede the earnings release. Holding above the prior $825–$830 high area would support the advance. Falling below the prior $797–$805 range would weaken the recovery; earnings can gap through chart levels.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.